Roche Ophthalmology
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 3 disclosed transactions, Roche Ophthalmology concentrates its licensing activity in Gastroenterology, Immunology. Roche Ophthalmology pays a 1.50x premium over market median. Their most common deal structure is Acquisition, with an average disclosed value of $7.1B. Most recent activity: 2023.
Pipeline coverage & gaps
Roche Ophthalmology has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| AcquisitionPrimary | 2 | $7.0B | $7.0B |
| Collaboration | 1 | — | $7.1B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2023 | RVT-3101 | Televant | inflammatory diseases | phase_3 | $7.0B | $7.0B |
| 2023 | RVT-3101 (RO7790121) | Roivant Sciences (Televant Holdings) | inflammatory bowel disease | phase_2 | $7.1B | $7.1B |
| 2020 | RVT-3101 (afimkibart) | Roivant Sciences | ulcerative colitis | phase_2 | — | $7.1B |
How this is computed
For each Roche Ophthalmology deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 3 disclosed deal premiums vs. peer medians. Raw premium 3.564, clamped to [0.7, 1.5].